Listed

Acurx Pharmaceuticals, Inc.: Form 10-Q for the period ended Jun 30, 2022

Filed with the SEC on Aug 12, 2022 and accepted by EDGAR at Aug 12, 2022, 16:07 ET.

Share

Sections

The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2022-06-30. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Research and development3 months2022-04-01 to 2022-06-30$911.7kus-gaap:ResearchAndDevelopmentExpense
Research and development6 months2022-01-01 to 2022-06-30$1.7mus-gaap:ResearchAndDevelopmentExpense
Selling, general and administrative3 months2022-04-01 to 2022-06-30$0us-gaap:SellingGeneralAndAdministrativeExpense
Selling, general and administrative6 months2022-01-01 to 2022-06-30$113.1kus-gaap:SellingGeneralAndAdministrativeExpense
Income tax6 months2022-01-01 to 2022-06-30$0us-gaap:IncomeTaxExpenseBenefit
Net income3 months2022-04-01 to 2022-06-30−$2.6mus-gaap:NetIncomeLoss
Net income6 months2022-01-01 to 2022-06-30−$5.3mus-gaap:NetIncomeLoss
Diluted EPS3 months2022-04-01 to 2022-06-30−$0.26us-gaap:EarningsPerShareDiluted
Diluted EPS6 months2022-01-01 to 2022-06-30−$0.52us-gaap:EarningsPerShareDiluted
Basic EPS3 months2022-04-01 to 2022-06-30−$0.26us-gaap:EarningsPerShareBasic
Basic EPS6 months2022-01-01 to 2022-06-30−$0.52us-gaap:EarningsPerShareBasic
Diluted shares (weighted)3 months2022-04-01 to 2022-06-3010,263,202 sharesus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Diluted shares (weighted)6 months2022-01-01 to 2022-06-3010,248,107 sharesus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Operating cash flow6 months2022-01-01 to 2022-06-30−$3.9mus-gaap:NetCashProvidedByUsedInOperatingActivities
Cash and equivalentsAt period end2022-06-30$9.1mus-gaap:Cash
Current assetsAt period end2022-06-30$9.2mus-gaap:AssetsCurrent
Total assetsAt period end2022-06-30$9.3mus-gaap:Assets
Current liabilitiesAt period end2022-06-30$473.9kus-gaap:LiabilitiesCurrent
Total liabilitiesAt period end2022-06-30$473.9kus-gaap:Liabilities

Source: SEC EDGAR, the filing index for accession 0001410578-22-002396. Last ingested by Listed: Nov 14, 2026, 21:17 ET. Listed shows no prices and gives no investment advice.